Structure Therapeutics Future Growth
Future criteria checks 2/6
Structure Therapeutics's earnings are forecast to decline at 21.9% per annum while its annual revenue is expected to grow at 36.4% per year. EPS is expected to grow by 2.8% per annum. Return on equity is forecast to be -80.1% in 3 years.
Key information
-21.9%
Earnings growth rate
2.8%
EPS growth rate
Pharmaceuticals earnings growth | 27.6% |
Revenue growth rate | 36.4% |
Future return on equity | -80.1% |
Analyst coverage | Good |
Last updated | 26 Jun 2024 |
Recent future growth updates
Recent updates
Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -226 | -239 | -188 | 7 |
12/31/2025 | 56 | -123 | -182 | -174 | 9 |
12/31/2024 | N/A | -132 | -186 | -125 | 9 |
3/31/2024 | N/A | -98 | -96 | -93 | N/A |
12/31/2023 | N/A | -90 | -82 | -79 | N/A |
9/30/2023 | N/A | -77 | -71 | -70 | N/A |
6/30/2023 | N/A | -66 | -60 | -60 | N/A |
3/31/2023 | N/A | -58 | -53 | -53 | N/A |
12/31/2022 | N/A | -53 | -46 | -46 | N/A |
9/30/2022 | N/A | -56 | -45 | -45 | N/A |
12/31/2021 | N/A | -44 | -33 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GPCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GPCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GPCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GPCR's revenue (36.4% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: GPCR's revenue (36.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GPCR is forecast to be unprofitable in 3 years.